Clinical Characteristics of Children with Short Stature and the Effect of Recombinant Human Growth Hormone Combined with Letrozole on p21waf/cip1,25-OH-D Levels
Objective To investigate the clinical value of recombinant human growth hormone(RH GH)combined with letrozole in the treatment of idiopathic short stature(ISS)and its effect on the levels of p21waf/cip1 and 25 hydroxy Vitamin D(25-OH-D)in children.Methods 86 children with ISS were selected and randomly divided into control group and study group,43 cases each;The control group was given RH GH,and the study group was treated with letrozole for 12 months.Bone age,PINP,predicted lifetime height,p21waf/cip1,bone alkaline phosphatase(BALP),25-OH-D,osteocalcin(OC),clinical efficacy and adverse reactions were compared between the two groups.Results The excellent and good rate of curative effect in the study group(95.35%vs 76.74%)was higher than that in the control group(P<0.05).Before treatment,there was no significant difference in bone age,PINP,predicted final height,BALP,OC,p21waf/cip1 protein,25-OH-D between the two groups(P>0.05);After 12 months of treatment,the PINP,bone age,25-OH-D,OC and predicted final height of the study group were larger than those of the control group,and the p21waf/cip1 protein and BALP of the study group were smaller than those of the control group,with statistical significance(P<0.05).There was no significant difference in the total adverse reaction rate between the two groups(11.63%vs 6.98%)(P>0.05).Conclusion Combined with letrozole on the basis of RH GH has a good effect on ISS,which can effectively improve the bone metabolism index and 25-OH-D,p21waf/cip1 levels of children,promote the height growth and bone development of children,and improve the lifelong height value of patients.
Idiopathic short statureRecombinant human growth hormonep21waf/cip125 hydroxy Vitamin DLetrozole
国家科技期刊平台
NSTL
万方数据
